Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
101-120 of 653 trials

Metastatic Breast Cancer: Somatostatin Receptor PET Scan Study

We are studying how somatostatin receptors behave in metastatic breast cancer using DOTATOC-68Ga PET scans. This may help us understand the disease better and improve future imaging techniques.

Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Acquired Hemophagocytic Syndrome: Ruxolitinib Study

We are studying whether ruxolitinib, combined with standard care, can improve organ function and survival in critically ill patients with acquired hemophagocytic syndrome. This trial also looks at the safety and effects of the drug on various health markers.

Haemophagocytic Syndrome1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyInternal Medicine

Chronic Lymphocytic Leukemia: Venetoclax and Obinutuzumab Study

We are assessing the effectiveness and safety of a combination treatment for adults with recurring chronic lymphocytic leukemia. This study aims to understand how well the treatment works and what side effects may occur.

Recurrent Chronic Lymphocytic Leukemia1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Hepatocellular Carcinoma: Livmoniplimab and Budigalimab Study

We are studying a combination of two medications for people with advanced liver cancer who have not had prior treatment. The goal is to find the best dose and assess safety and effectiveness.

Metastatic Liver Cancer1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHepatologyOncology

Colorectal Liver Metastases: SGM-101 and Indocyanine Green Imaging

We are studying the use of two imaging agents during surgery for colorectal liver metastases to see if they help surgeons remove cancerous tissue more effectively. This trial aims to improve surgical accuracy and patient outcomes.

Liver Metastases1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineOncology

Anti-NMDA Receptor Encephalitis: Inebilizumab Study

We are testing a new treatment called inebilizumab for people with anti-NMDA receptor encephalitis. The study aims to see if it helps improve disability compared to a placebo.

Anti-NMDA Receptor Encephalitis1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicineNeurology

Guselkumab for Active Psoriatic Arthritis Axial Disease

We are studying whether guselkumab can help reduce symptoms in people with active psoriatic arthritis axial disease who have not been treated before. Participants will receive either the medication or a placebo.

Psoriatic Arthritis1-2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Cushing’s Disease: Lu AG13909 Treatment Study

We are investigating a new medication, Lu AG13909, for adults with Cushing’s disease to see how it affects cortisol levels and its safety. This trial aims to improve understanding of this rare condition and its treatment options.

Cushing's Disease1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Guselkumab for Pediatric Crohn’s Disease

We are studying the safety and effectiveness of guselkumab in children with moderately to severely active Crohn’s disease. This trial aims to see how well the treatment works after initial positive responses.

Crohn's Disease1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

New Surgical Treatment for Wet AMD: Vitrectomy and TPA

We are studying a new surgical approach for people with submacular hemorrhage caused by wet AMD. This trial compares it to the standard treatment to see if it improves vision and eye health.

Exudative Age-Related Macular Degeneration1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOphthalmology

Chronic Pouchitis in Children: Vedolizumab IV Study

We are testing the intravenous medication vedolizumab in children with active chronic pouchitis to see if it helps them achieve remission. The study will also look at how well the treatment is tolerated and its overall effectiveness.

Pouchitis1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Advanced Solid Tumors: STX-478 Treatment Study

We are investigating the effects of STX-478 alone and with other cancer drugs for people with advanced solid tumors. This study aims to see how well these treatments work together.

Breast CancerAdvanced Solid TumorsHead and Neck Squamous Cell Carcinoma1-2 yearsSafety phase (I)Efficacy phase (II)Oncology

Chronic Migraine: Dysport Treatment Study

We are studying whether Dysport can help reduce the number of migraine days in adults with chronic migraines. The trial will also look at its safety and overall effectiveness compared to a placebo.

Chronic Migraine1-2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteNeurology

Advanced Solid Tumors: GRWD5769 Treatment Study

We are testing the safety and effectiveness of GRWD5769 alone and with cemiplimab in patients with advanced solid tumors. This study aims to find out how well these treatments work and their tolerability.

Malignant Solid Tumor1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Chronic Kidney Disease: Finerenone Safety Study

We are studying the long-term safety of finerenone for children and young adults with chronic kidney disease. This trial looks at its effects when used alongside standard treatments like ACE inhibitors or ARBs.

Chronic Kidney DiseaseProteinuria1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrologyPediatrics

Progressive Pulmonary Fibrosis: Inhaled Treprostinil Study

We are investigating whether inhaled treprostinil can improve lung function in people with progressive pulmonary fibrosis. The study will also assess its safety and impact on overall health.

Progressive Pulmonary Fibrosis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesPulmonology

HIV and Liver Health: Doravirine Study

We are exploring how the medication Doravirine affects liver fat and fibrosis in people living with HIV who have liver issues. This study aims to see if switching to Doravirine improves liver health over time.

Human Immunodeficiency Virus (HIV)1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesHepatologyInfectious DiseasesInternal Medicine

Childhood Onset Nephrotic Syndrome: Obinutuzumab vs. MMF

We are studying whether obinutuzumab is more effective and safer than MMF for children with childhood onset idiopathic nephrotic syndrome. We will also look at how these treatments affect fatigue and quality of life.

Childhood Idiopathic Nephrotic Syndrome1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology

Efruxifermin for Non-Cirrhotic NASH/MASH

We are studying whether Efruxifermin can improve liver health and reduce fibrosis in people with Non-Cirrhotic NASH or MASH. Participants will be compared to those receiving a placebo to assess safety and effectiveness.

Non-alcoholic Fatty Liver DiseaseHepatic Fibrosis1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesEndocrinologyHepatology

Innovative Cell Therapy for Autoimmune Xerostomia

We are studying a new treatment using fat-derived cells for patients with autoimmune xerostomia. The goal is to see if it can improve symptoms and is safe to use.

Autoimmune Xerostomia1-2 yearsSafety phase (I)Efficacy phase (II)OtolaryngologyRheumatology